PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2
暂无分享,去创建一个
F. Christians | R. Parsons | J. Oliner | D. Liaw | Jing Li | L. Simpson | Ian Hennessy | Laura Simpson
[1] R. Hammer,et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. , 2000, Molecular cell.
[2] C. Kahn,et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. , 2000, Molecular cell.
[3] Francisca Vazquez,et al. Phosphorylation of the PTEN Tail Regulates Protein Stability and Function , 2000, Molecular and Cellular Biology.
[4] J. Olefsky,et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.
[5] S. Sciacchitano,et al. Different subcellular localization and phosphoinositides binding of insulin receptor substrate protein pleckstrin homology domains. , 2000, Molecular endocrinology.
[6] T. P. Neufeld,et al. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. , 2000, Developmental biology.
[7] Joseph Schlessinger,et al. A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling , 2000, Molecular and Cellular Biology.
[8] Y. Kido,et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. , 2000, The Journal of clinical investigation.
[9] G. Prestwich,et al. Expression Cloning of Protein Targets for 3-Phosphorylated Phosphoinositides* , 1999, The Journal of Biological Chemistry.
[10] D. Goberdhan,et al. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. , 1999, Genes & development.
[11] E. Hafen,et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. , 1999, Development.
[12] E. Kandel,et al. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. , 1999, Experimental cell research.
[13] L. Schriml,et al. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.
[14] S. R. Datta,et al. Cellular survival: a play in three Akts. , 1999, Genes & development.
[15] C. Eng,et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. , 1999, Cancer research.
[16] D. Leroith,et al. Phosphorylation of Insulin Receptor Substrate-1 (IRS-1) by Protein Kinase B Positively Regulates IRS-1 Function* , 1999, The Journal of Biological Chemistry.
[17] C. Borland,et al. The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] K. Guan,et al. Negative Regulation of the Forkhead Transcription Factor FKHR by Akt* , 1999, The Journal of Biological Chemistry.
[19] F. Christians,et al. Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1 , 1999, Cell.
[20] H. Wu,et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] Geert J. P. L. Kops,et al. Direct control of the Forkhead transcription factor AFX by protein kinase B , 1999, Nature.
[22] R. Roth,et al. Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation by an Akt/Phosphatidylinositol 3-Kinase Pathway* , 1999, The Journal of Biological Chemistry.
[23] Lewis C. Cantley,et al. The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function* , 1999, The Journal of Biological Chemistry.
[24] M. Greenberg,et al. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.
[25] J. Lees,et al. Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] C. Cordon-Cardo,et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Ritz,et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. , 1999, Human molecular genetics.
[28] Hong Sun,et al. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[29] C. Sawyers,et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] R. Parsons,et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. , 1998, Cancer research.
[31] G. Ruvkun,et al. The taxonomy of developmental control in Caenorhabditis elegans. , 1998, Science.
[32] G. Mills,et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. , 1998, Cancer research.
[33] M. White,et al. Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells. , 1998, Endocrinology.
[34] G. Ruvkun,et al. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. , 1998, Molecular cell.
[35] W. Cavenee,et al. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. , 1998, Cancer research.
[36] José Luis de la Pompa,et al. Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.
[37] Carlos Cordon-Cardo,et al. Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.
[38] R. Levine,et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. , 1998, Cancer research.
[39] D. Accili,et al. Evidence That IRS-2 Phosphorylation Is Required for Insulin Action in Hepatocytes* , 1998, The Journal of Biological Chemistry.
[40] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[41] G. Shulman,et al. Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.
[42] K. Kinzler,et al. A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Leroith,et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. , 2009, The Journal of biological chemistry.
[44] Hanlee P. Ji,et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. , 1997, American journal of human genetics.
[45] A. Berchuck,et al. PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.
[46] Kathleen R. Cho,et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.
[47] M. White,et al. The IRS‐signalling system during insulin and cytokine action , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.
[48] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[49] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[50] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[51] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[52] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[53] L. Cantley,et al. Phosphoinositide 3-kinase and the regulation of cell growth. , 1996, Biochimica et biophysica acta.
[54] T. Katada,et al. Synergistic activation of PtdIns 3-kinase by tyrosine-phosphorylated peptide and beta gamma-subunits of GTP-binding proteins. , 1996, The Biochemical journal.
[55] N. Sonenberg,et al. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice , 1996, Molecular and cellular biology.
[56] L. Cantley,et al. Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins , 1995, Cell.
[57] C. Kahn,et al. 4PS/Insulin Receptor Substrate (IRS)-2 Is the Alternative Substrate of the Insulin Receptor in IRS-1-deficient Mice (*) , 1995, The Journal of Biological Chemistry.
[58] M. White,et al. Regulation of Phosphatidylinositol 3′-Kinase by Tyrosyl Phosphoproteins , 1995, The Journal of Biological Chemistry.
[59] N. Rosen,et al. Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[60] E. Van Obberghen,et al. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. , 1994, The Journal of biological chemistry.
[61] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[62] C. Kahn,et al. Expression and function of IRS-1 in insulin signal transmission. , 1992, The Journal of biological chemistry.
[63] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[64] L. Cantley,et al. Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. , 1991, Methods in enzymology.